Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2015-07-21 / J Immunother Cancer 2015;3:32Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
/in International Publications, Newcastle Disease Virus /von 2015-06-26 / Mol. Ther. 2015 Oct;23(10):1630-40Vaccination of multiple myeloma: Current strategies and future prospects
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2015-06-18 / Crit. Rev. Oncol. Hematol. 2015 Nov;96(2):339-54Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-06-17 / J Clin Oncol 33, 2015 (suppl; abstr e13030)Brain Tumor Immunotherapy: What have We Learned so Far?
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-06-17 / Front Oncol 2015;5:98Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-32Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2015-06-11 / Viruses 2015 Jun;7(6):2980-98Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2015-06-02 / Front Immunol 2015;6:271Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr 2036)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de